SNARE based peptide linking as an efficient strategy to retarget botulinum neurotoxin’s enzymatic domain to specific neurons using diverse neuropeptides as targeting domains [PDF]
, 2011 Many disease states are caused by miss-regulated neurotransmission. A small fraction of these diseases can currently be treated with botulinum neurotoxin type A (BoNT/A).
, +6 more
core
Rare GNAO1 Variant Presenting with Deep Brain Stimulation‐Responsive Jaw‐Opening Dystonia
Movement Disorders Clinical Practice, EarlyView.
Fabian Maass +4 more
wiley +1 more source
Definition and Classification of Dystonia
Movement Disorders, EarlyView.Abstract Dystonia is a movement disorder with varied clinical features and diverse etiologies. Here we present a revision of the 2013 consensus definition and classification of dystonia in light of subsequent publications and experience with its application during the last decade.
Alberto Albanese +13 more
wiley +1 more source
The role of the host—Neutrophil biology
Periodontology 2000, EarlyView., 2023 Abstract Neutrophilic polymorphonuclear leukocytes (neutrophils) are myeloid cells packed with lysosomal granules (hence also called granulocytes) that contain a formidable antimicrobial arsenal. They are terminally differentiated cells that play a critical role in acute and chronic inflammation, as well as in the resolution of inflammation and wound ...
Iain L. C. Chapple +4 more
wiley +1 more source
Botulinum Toxins and Lip Repositioning Surgery with Repeated Botulinum Toxin Injection: A Combined Approach for Gummy Smile Treatment. [PDF]
Plast Reconstr Surg Glob Open, 2023 Adel N.
europepmc +1 more source
Inhibitory effect of ganglioside GTlb on the activities of Clostridium botulinum toxins
, 1984 Ganglioside GTlb inactivated botulinum toxins. The inactivation of type A, B, E and F toxins was marked but that of type C and D was less. Inactivation of type A toxin by ganglioside was significantly inhibited by one of two toxin fragments.
S. Kozaki +4 more
semanticscholar +1 more source
Challenging the Clostridium botulinum toxin type A (BoNT/A) with a selection of microorganisms by culture methods and extended storage of used vials to assess the loss of sterility [PDF]
, 2015 In 2002, botulinum toxin type A (BoNT/A) was approved by the US Food and Drug Administration (FDA) for cosmetic use. However, there may be procedural differences between the ways in which a clinician handles, applies and stores the product compared to ...
Crean, Stjohn +4 more
core
Adult‐Onset Dystonia‐Parkinsonism: Do Not Forget SERAC1
Movement Disorders Clinical Practice, EarlyView.
Giulia Scacciatella +15 more
wiley +1 more source
In Silico Conformational Features of Botulinum Toxins A1 and E1 According to Intraluminal Acidification. [PDF]
Toxins (Basel), 2022 Cottone G +6 more
europepmc +1 more source
Interstitial Cystitis/Bladder Pain Syndrome in Men
Neurourology and Urodynamics, EarlyView.ABSTRACT Aims In April 2025, the Wake Forest Institute for Regenerative Medicine hosted a Global Consensus meeting on interstitial cystitis/bladder pain syndrome (IC/BPS) in Winston‐Salem, NC. The goal of this meeting was to establish attainable targets in phenotyping, diagnosis, and biomarkers for IC/BPS.
Madeline Snipes +5 more
wiley +1 more source